Source: earnings_events
Changes History →Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
Investment research built around change detection.
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
What changed: Target Corporation (TGT) reported EPS of $2.65 vs. consensus estimate of $2.08, beating estimates by 27.4% on 2026-11-18.
Source: earnings_events
Related research: Target (TGT) Jumps Toward a 52-Week High on a Traffic-Led Q3 Beat and a Raised Sales Outlook →
TGT earnings scheduled for 2027-03-02, with consensus EPS estimate of $2.70.
What changed: Okta, Inc. (OKTA) moved +9.90% from $177.99 to $195.61 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on elevated volume (2.3x the 5-day average), suggesting institutional interest, though the trigger remains unclear.
Source: daily_prices:fmp_change_percent
Changes History →Okta's earnings announcement on 2026-12-01 (consensus EPS estimate $0.93) will test whether the stock's strength holds.
What changed: Generac Holdings Inc. (GNRC) moved +8.76% from $188.91 to $205.45 on 2026-11-18 after the company's PWRmicro microinverter won Best in Show at the 2026 Solar Power World Top Products Awards. Volume traded was 2.3x the 5-day average, indicating elevated institutional interest.
Source: daily_prices:fmp_change_percent
Changes History →GNRC earnings scheduled for 2026-02-10 will provide updated guidance and shipment trends for the PWRmicro product line.
What changed: Woodward, Inc. (WWD) reported EPS of $2.83 vs. consensus estimate of $2.54, beating by 11.4%.
Source: earnings_events
Changes History →Monitor WWD's next earnings announcement (currently scheduled for 2026-11-23, pending confirmation) for guidance on sustaining this operational momentum.
What changed: Everpure, Inc. (P) reported EPS of $0.86 vs. $0.78 consensus estimate, beating by 10.8% on 2026-11-18.
Source: earnings_events
Changes History →P's next earnings announcement scheduled for 2026-12-01.
What changed: Macy's, Inc. (M) moved +6.92% from $23.27 to $24.88 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume was 1.6x the 5-day average, suggesting modest institutional interest ahead of the company's third-quarter 2026 earnings announcement scheduled for December 2, 2026.
Source: daily_prices:fmp_change_percent
Changes History →Macy's third-quarter 2026 earnings announcement on December 2, 2026 — the consensus expects a loss per share; any beat could validate the pre-announcement move.
What changed: Karman Holdings Inc. (KRMN) moved -5.16% from $36.05 to $34.19 on 2026-11-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, suggesting modest institutional participation in the decline.
Source: daily_prices:fmp_change_percent
Changes History →Karman Holdings' earnings announcement (scheduled for 2026-03-24, pending confirmation) with consensus EPS estimate of $0.23.
What changed: Commvault Systems, Inc. (CVLT) moved +6.21% from $142.13 to $150.95 on 2026-11-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →Monitor for CVLT earnings announcement on 2027-01-26 for confirmation of forward guidance and execution.
What changed: Brinker International, Inc. (EAT) moved +5.10% from $193.56 to $203.43 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on volume near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →Monitor the Q1 FY2027 earnings announcement (2027-01-27) against the consensus EPS estimate of $3.37 for confirmation of underlying momentum.
What changed: Oscar Health, Inc. (OSCR) moved -7.58% from $29.83 to $27.57 on November 18, 2026, reaching a new 30-day low on modestly elevated volume (1.7x the 5-day average). The pullback followed a steep year-to-date run-up of roughly 95%–108% and occurred despite no major negative company announcement on the day itself. Profit-taking appears to have intensified after the stock slipped below its 50-day moving average earlier in November, with traders consolidating positions after the company's November 5 Q3 2026 earnings report (which raised full-year 2026 guidance for a third time) and amid investor caution around 2027 expansion execution and healthcare costs.
Source: daily_prices:fmp_change_percent
Changes History →Oscar Health is scheduled to report Q4 2026 earnings on February 9, 2027 (consensus EPS estimate: −$1.08); watch for any updates on 2027 expansion progress and medical cost guidance.
What changed: Scholar Rock Holding Corporation (SRRK) moved +6.93% on November 18, 2026, following management presentations at the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference. At Jefferies on November 17, management highlighted strong early demand for ISEMBYLD (apitegromab-mstn), the company's FDA-approved spinal muscular atrophy therapy, despite typical rare-disease launch challenges around reimbursement and billing codes.
Source: daily_prices:fmp_change_percent
Changes History →Q3 2026 results (reported November 10) showed $0.57 million in revenue and a $205 million PRV sale; watch for Q4 revenue and ISEMBYLD patient uptake metrics in the next earnings report scheduled for March 2, 2027.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.

Target (TGT) Jumps Toward a 52-Week High on a Traffic-Led Q3 Beat and a Raised Sales Outlook
Target (TGT) jumped more than 5% on November 18, pushing toward its 52-week high after a traffic-led fiscal third-quarter beat — a gain that substantially outpaced flat big-box peers and the broad market. EPS of $2.65 (GAAP and adjusted alike) cleared the ~$2.07 expected, but about $0.50 came from a one-time $301 million tariff refund, leaving underlying EPS near $2.15 (still up ~21% year over year). What mattered more was the mix: comparable sales rose 5.6%, driven by a 5.0% gain in traffic — more shoppers, the proof point for a company whose slump was a traffic problem — though the category recovery stayed uneven, with apparel and home soft. Target also raised its full-year sales-growth outlook to around 6%. The catch is price: after more than doubling off an $83 low, the stock sits near its 52-week high and above the analysts' average target of ~$165.56, with only a Hold consensus, so much of the initial re-rating may already be reflected and the holiday quarter now has to confirm the recovery.

Disney (DIS) Nears a 52-Week High on a Q4 Beat, a 33% Dividend Hike, and a $3 Billion Savings Target
The Walt Disney Company rose about 2.5% to roughly $122 — within about 1% of a 52-week high — on November 17 after reporting fiscal fourth-quarter results, outperforming flat media peers and the broader market. Revenue rose 16% to $25.9 billion (though an extra 53rd week flatters that to roughly 8% underlying) and adjusted EPS of $1.77 beat expectations, with the standout being streaming: operating income more than doubled to $824 million (about +65% excluding the extra week), confirming the direct-to-consumer business is becoming meaningfully profitable. Management paired the beat with a shareholder-friendly message — a 33% dividend increase (to $2.00 a year) and a target of about $3 billion in annual cost savings by fiscal 2029 — while reaffirming double-digit adjusted-EPS growth in fiscal 2027 and, notably, raising content spending ~9% to roughly $26 billion, so this is still a growth-and-invest story. The turnaround, initiated under Bob Iger and now led by CEO Josh D'Amaro, is clearly working — but the catch is price: the stock has risen ~14% in a year to near its 52-week high, with only ~5% upside to the average analyst target, so much of it is already in the shares.

DoorDash's $17 Billion Instacart Takeover Heads to a DOJ Antitrust Review
DoorDash's roughly $17 billion, $65-a-share acquisition of Instacart now heads to a U.S. Department of Justice antitrust review, Reuters and Bloomberg reported — the DOJ, not the FTC, taking the lead on a deal to combine the top restaurant-delivery and online-grocery platforms. A review is not a challenge, and both companies still target a late-2027/early-2028 close, but with CART near $59 versus the $65 offer, the ~11% spread tells the real story: time, regulatory risk, and a stock-heavy slice of the consideration that floats with a falling DoorDash.

Summit Therapeutics (SMMT) Plunges ~16% to a 52-Week Low After the FDA Rejects Ivonescimab's First US Filing
Summit Therapeutics plunged about 16% to roughly $11.82 — a fresh 52-week low — on November 16 after disclosing that the FDA had issued a Complete Response Letter (a rejection, for now) for its lead drug, ivonescimab. The move was emphatically company-specific: on a day the broad market and biotech indexes each fell about 2%, Summit dropped eight times as hard. The CRL covers ivonescimab plus chemotherapy after EGFR-targeted treatment in non-small cell lung cancer, from the Phase 3 HARMONi trial — which clearly met its progression-free survival goal (6.8 vs 4.4 months) but whose primary overall-survival analysis narrowly missed significance (16.8 vs 14.0 months, HR 0.79, p=0.057), and the FDA judged the benefit-risk insufficient. Crucially, this is not a verdict that the drug fails to extend life: in a separate first-line trial (China's HARMONi-2) ivonescimab beat Keytruda on overall survival (30.8 vs 22.6 months, HR 0.73, p=0.009). Several things keep the CRL from being thesis-ending: it covers one smaller indication; the far larger global first-line opportunity (HARMONi-3, HARMONi-7) is still ahead; and just six weeks earlier AstraZeneca completed a $2 billion strategic investment in Summit. Even after the drop, Summit is a ~$9.4 billion company with roughly $2.6 billion of liquidity (including the AstraZeneca cash) and ~27%-of-float short interest — a well-funded, AstraZeneca-backed, polarizing bet whose value rests almost entirely on first-line survival data still to come.

Tyson Foods (TSN) Jumps ~7% on a Better-Than-Feared Q4 and an Outlook for Sharply Narrower Beef Losses
Tyson Foods jumped about 7% to roughly $62.80 on November 16 after reporting fiscal fourth-quarter results — and it did so on a risk-off day, with the S&P 500 down nearly 2% as the AI, chip and crypto trades sold off. For a defensive consumer-staples name to rise ~7% while the market fell is a clear company-specific signal, reinforced by a rotation into cheap, low-beta stocks. Tyson's adjusted EPS of $0.61 was roughly in line with or slightly above commonly cited consensus estimates, but it was down ~47% year over year, and on a GAAP basis the company posted a $0.22-per-share loss; revenue of $14.6 billion beat but underlying sales fell ~4%, and adjusted operating income dropped 41%. What drove the jump was the outlook — specifically for beef: management guided its Beef segment from a $654 million fiscal-2026 loss toward roughly breakeven in 2027 (a $300 million loss to a $100 million profit), a sharp narrowing of the biggest drag on earnings caused by a historic cattle shortage, even though total-company adjusted operating-income guidance ($1.7–$2.15 billion) is roughly flat versus this year's $1.977 billion. The stock looks cheap on sales (~0.4x) and reasonable on forward earnings (~16x), but after the pop it sits right at the analysts' average target with a Hold rating — so the move reads as a weak-but-better-than-feared quarter plus a credible beef-loss turn, re-rating a beaten-down defensive in one session.

Black Hills and NorthWestern Complete Their Merger to Form Bright Horizon Energy (NYSE: HZN)
Black Hills and NorthWestern Energy completed an all-stock merger of equals on November 13, 2026, forming Bright Horizon Energy (NYSE: HZN) — a roughly $12 billion regulated utility serving about 2.2 million electric and gas customers across eight states, with a growing pipeline of data-center electricity demand.











